-
Loading metrics
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
- Kerrie Faia,
- Kerry White,
- Erin Murphy,
- Jennifer Proctor,
- Melissa Pink,
- Nicole Kosmider,
- Karen McGovern,
- Jeffery Kutok
x
- Published: August 1, 2018
- https://doi.org/10.1371/journal.pone.0200725